Considering that WMW reduces IL-1β expression in patients with inflammatory bowel disease [30] and inhibits the activation of the NLRP3 inflammasome in vitro [31], we hypothesize that WMW protects pancreatic β cells by alleviating the inflammation states through the inhibition of the NLRP3 inflammasome activation and thus prevents T2DM development. The gene discussed is NLRP3; the disease is inflammatory bowel disease.